Updated:
Boehringer Ingelheim Venture
Boehringer Ingelheim Venture was established in 2010 as the corporate venture arm of Boehringer Ingelheim. It concentrates on pharmaceutical and medical...
Overview
Boehringer Ingelheim Venture was established in 2010 as the corporate venture arm of Boehringer Ingelheim. It concentrates on pharmaceutical and medical technology companies. The firm pursues early-stage opportunities including seed, start-up and spin-off transactions. Investments occur worldwide in vaccines, new biological entities and regenerative medicine. Confirmed strategy elements include divestiture alongside venture commitments. AUM stands at an estimated 301 million USD. No additional offices or team size figures are recorded. No operational events from the last 24 months appear in available records. The unit maintains direct ties to its corporate parent, shaping mandate and exit options through internal alignment rather than external LP structures.
General information
Firm type
Venture Capital
Year founded
2010
Location
Region
Europe
Country
Germany
City
Ingelheim am Rhein
Corporate office
Ingelheim am Rhein, Germany
Sector focus
Frequently asked questions
Who runs investment decisions at Boehringer Ingelheim Venture?
No named principals or investment committee members are disclosed in available records.
Does Boehringer Ingelheim Venture participate in fund commitments or only direct deals?
The firm executes direct early-stage investments and spin-offs. No fund commitments are referenced.
What investment stages does Boehringer Ingelheim Venture typically target?
The firm focuses on seed, start-up and early-stage opportunities.
Profile maintained by Altss. Updated: . To correct this record or make a privacy request, send the page URL and your evidence to privacy@altss.com; corrections are free.
Need institutional-grade insight on venture capital firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: